{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:24Z","timestamp":1791924204797,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1053\/j.ajkd.2016.11.024","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T06:17:08Z","timestamp":1486621028000},"page":"701-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma"],"prefix":"10.1053","volume":"69","author":[{"given":"Erik L.","family":"Lum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphamai","family":"Bunnapradist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Danovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2016.11.024_bib1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0041-1345(98)01987-3","article-title":"Post transplant malignancies","volume":"21","author":"Penn","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1053\/j.ajkd.2016.11.024_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"issue":"17","key":"10.1053\/j.ajkd.2016.11.024_bib3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among U.S. solid organ transplant recipients: the Transplant Cancer Match Study","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1053\/j.ajkd.2016.11.024_bib4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/TP.0b013e318270bc7b","article-title":"Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database","volume":"94","author":"Sampio","year":"2012","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ajkd.2016.11.024_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jamcollsurg.2010.10.018","article-title":"First use of intravenous chemotherapy cancer treatment: rectifying the record","volume":"212","author":"Fenn","year":"2011","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1053\/j.ajkd.2016.11.024_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ijc.2910280607","article-title":"Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in\u00a0vitro by culture with interleukin 2","volume":"28","author":"Hersey","year":"1981","journal-title":"Int J Cancer"},{"issue":"suppl 8","key":"10.1053\/j.ajkd.2016.11.024_bib7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/1097-0142(19860415)57:8+<1666::AID-CNCR2820571306>3.0.CO;2-J","article-title":"Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma","volume":"57","author":"Hersey","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.ajkd.2016.11.024_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.1989.7.4.486","article-title":"Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines","volume":"7","author":"Margolin","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1053\/j.ajkd.2016.11.024_bib9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts it inhibitor action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1053\/j.ajkd.2016.11.024_bib10","first-page":"201","article-title":"Thalidomide-effect on T cell subsets as a possible mechanism of action","volume":"53","author":"Moncada","year":"1985","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"16","key":"10.1053\/j.ajkd.2016.11.024_bib11","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2004.05.984","article-title":"Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma","volume":"22","author":"Richardson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2016.11.024_bib12","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.024_bib13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.024_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib,\u00a0lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Steward","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.024_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.11.024_bib16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2016.11.024_bib17","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B1-CD28 pathway","volume":"103","author":"Le Blanc","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.ajkd.2016.11.024_bib18","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by\u00a0increased Th-1 type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.ajkd.2016.11.024_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1053\/j.ajkd.2016.11.024_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GVHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"issue":"5971","key":"10.1053\/j.ajkd.2016.11.024_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"9","key":"10.1053\/j.ajkd.2016.11.024_bib22","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3109\/10428194.2014.914203","article-title":"Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide","volume":"55","author":"Montefusco","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.ajkd.2016.11.024_bib23","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.12391","article-title":"Fatal cardiac and renal allograft rejection with lenalidomide therapy for light chain amyloidosis","volume":"13","author":"Meyers","year":"2013","journal-title":"Am J Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617300057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617300057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:58:00Z","timestamp":1759460280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617300057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0272638617300057"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.024","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}